Caregiver Impressions of Disease and Change in Infants and Children Aged 6 Months to 5 Years with Moderate-To-Severe Atopic Dermatitis

Background: For infants and young children with atopic dermatitis (AD), assessment of disease activity and impact often relies on caregiver observations, as patients may be too young to reliably report symptoms and respond to questions. In clinical studies, caregiver assessments offer a complementary measure to evaluate treatment effects on behalf of patients. We assessed global caregiver impressions of AD severity and improvement of symptoms in patients aged 6 months to 5 years with moderate-to-severe AD treated with dupilumab for 16 weeks.

Methods: Children aged 6 months to 5 years with moderate-to-severe AD were enrolled in LIBERTY AD PRESCHOOL (NCT03346434), a randomized, double-blind, placebo-controlled, Phase 3 clinical trial of dupilumab. Patients received weight-tiered subcutaneous dupilumab (bodyweight 5 to <15 kg: 200 mg; 15 to <30 kg: 300 mg) or matched placebo, plus low-potency topical corticosteroids, every 4 weeks for 16 weeks. Caregivers were asked to rate their child’s symptoms throughout the treatment period according to the Caregiver Global Impression of Disease scoring (CGID; 1–no symptoms, 2–mild, 3–moderate, 4–severe, 5–very severe) and compare their child’s eczema to baseline symptoms using the Caregiver Global Impression of Change (CGIC; 1–much better, 2–moderately better, 3–a little better, 4–no change, 5–a little worse, 6–moderately worse, 7– much worse). The proportions of caregivers giving a score of 1 and/or 2 were compared between the dupilumab and placebo groups using a Cochran-Mantel-Haenszel test stratified by region, baseline disease severity, and baseline weight group.

Results: This analysis included 162 patients, of whom 83 were randomized to dupilumab and 79 were randomized to placebo. According to the CGID scoring, 17.8% more caregivers in the dupilumab group reported “mild or no symptoms” after 2 weeks of treatment compared with the placebo group (22.9% dupilumab vs 5.1% placebo; P=0.0015). By Week 16 of treatment, 46.3% more caregivers in the dupilumab group reported “mild or no symptoms” compared with the placebo group (51.8% dupilumab vs 5.5% placebo; P<0.0001). According to the CGIC scoring, 21.7% more caregivers in the dupilumab group described their child’s symptoms as “much better” after 2 weeks of treatment compared with the placebo group (21.7% dupilumab vs 0% placebo; P<0.0001). By Week 16 of treatment, 40.6% more caregivers in the dupilumab group described symptoms as “much better” compared with the placebo group (45.0% dupilumab vs 4.4% placebo; P<0.0001). Safety was consistent with the known safety profile of dupilumab.

Conclusions: Caregivers reported meaningful changes in AD severity in infants and young children aged 6 months to 5 years treated with dupilumab. Significantly better ratings were given in the dupilumab group compared with placebo as early as Week 2, with consistent improvements observed throughout 16 weeks of treatment.